Understanding Efficacy, Safety, and PSA Kinetics of Apalutamide Plus ADT in Patients With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

News
Video

Sponsored Content: Neal Shore, MD, FACS reviews new data on the TITAN trial of apalutamide in patients with mCSPC.

Sponsored Content: Neal Shore, MD, FACS reviews new data on the TITAN trial of apalutamide in patients with mCSPC.

This content is not certified for continuing education. The speaker has been compensated by Janssen Biotech, Inc.

Related Videos
Jeffrey P. Townsend, PhD
Rohan Garje, MD
Josep Maria Piulats Rodriguez, MD, PhD
Angela Jia, MD, PhD, of University Hospitals
Rohan Garje, MD, chief, Genitourinary Medical Oncology, Baptist Health Miami Cancer Institute
Kara N. Maxwell, MD, PhD
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Jeffrey P. Townsend, PhD
Related Content
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

May 6th 2024
Article
Neeraj Agarwal, MD

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

July 17th 2023
Podcast
Stephen J. Freedland, MD

Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC

May 4th 2024
Article
Andrew J. Armstrong, MD, MSc

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

June 15th 2023
Podcast
prostate cancer

Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

May 3rd 2024
Article
18F-PSMA-1007 PET/CT in Prostate Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer

May 3rd 2024
Article